Triple-negative breast cancer (TNBC) is an aggressive form of the disease that accounts for 15% of all breast cancer cases.

Renal + Urology News highlighted research led by the University of Cincinnati's Alberto Martini, MD, that found using ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.

A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and ...

The BC Cancer Foundation is launching a fundraising campaign to support the next three years of immunotherapy research at BC ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug ...

Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for ...

CAR-T-cell therapy treated a girl with a rare childhood cancer, raising hopes for future recipients of the approach.

A couple of years ago, New Atlas covered how treating Hodgkin lymphoma, a cancer of the lymphatic system, by combining an immunotherapy drug with chemotherapy led to greatly improved remission ...